Stocks · News reference
Outlook Therapeutics (NASDAQ: OTLK) to release Q3 earnings on Aug. 14. Analysts expect a loss of 8 cents/share. Analysts rate it Neutral or Buy.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-27 AccNo: 0001104659-26-102446 Size: 366 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
BTIG analyst Julian Harrison reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintains $4 price target.
Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.